Medicines and Healthcare products Regulatory Agency grants conditional authorisation to Merck's molnupiravir, which can be used to treat symptomatic COVID-19 patients
The Medicines and Healthcare products Regulatory Agency grants conditional authorisation to Merck's molnupiravir, which can be used to treat symptomatic COVID-19 patients, making the United Kingdom the first country to approve the world's first COVID-19 antiviral oral drug.
Herald Premium Archive
This report is for subscribers
Sign in or choose a plan to read this report and the complete Premium retrospective archive.
HealthMedicines and Healthcare products Regulatory Agency grants conditional authorisation to Merck's molnupiravir, which can be used to treat symptomatic COVID-19 patients
View Premium plansBrowse free archive reportsThe Medicines and Healthcare products Regulatory Agency grants conditional authorisation to Merck's molnupiravir, which can be used to treat symptomatic COVID-19 patients, making the United Kingdom the first country to approve the world's first COVID-19 antiviral oral drug.